Disclosures: All presenters are employees of Kyowa Hakko Kirin Co., Ltd. This study was funded by Kyowa Hakko Kirin Co., Ltd. Cholinesterase inhibitors (ChEI) that restore brain cholinergic function mitigate clinical symptoms and have become the mainstay of treatment for Alzheimer's disease (AD) in spite of their generally small effect size, dose-limiting side effects, and need for prolonged initial dose titration. PET imaging studies reveal that ChEIs given at their maximum tolerated dose (MTD) inhibit the target enzyme in brain by only about 30 %, while animal model and clinical trial reports suggest that higher ChEI doses confer greater cognitive benefit. We thus hypothesized that the co-administration of a peripheral anticholinergic to block dose limiting AEs might enable use of higher ChEI doses and thus improve antidementia efficacy. To initiate evaluation of this possibility, phase I single blind, placebo-controlled, cross-over, dose-escalation studies have been conducted in healthy male volunteers. One trial compared oral donepezil monotherapy with donepezil (to 40 mg/day) given with the peripherally acting anticholinergic solifenacin (10 mg/day). Another compared transdermal rivastigmine (to 27.6 mg/day release) given alone or with a transdermal anticholinergic. The addition of an anticholinergic reduced AEs by as much as 90 %, thus enabling mean ChEI MTD and peak plasma concentration increments to be safely and tolerably increased by three-to fourfold (p<.05). Titration time to MTD was shortened to a few days with all drug combinations. A placebo-controlled phase II superiority trial of donepezil plus solifenacin is now ongoing in moderate AD patients to evaluate the effect of higher ChEI doses on cognitive function. Financial Source: Chase Pharmaceuticals Corp.
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The Era of Blood-derived Biomarkers Defining Preclinical Alzheimer's Disease is Ready for Prime Time!! Massimo S. Fiandaca, Georgetown University; Mark Mapstone, University of Rochester; Xiaogang Zhong, Amrita K. Cheema, and Howard J. Federoff, Georgetown University Recent high profile efficacy failures in late-stage therapeutic clinical trials for prodromal or manifest Alzheimer's disease (AD) have been very disappointing to patients, clinicians, and scientists, and extremely costly to the biopharmaceutical industry. Patient selection criteria for these studies have been based primarily on neurocognitive documentation of either mild cognitive impairment (MCI) or various stages of AD. These unsuccessful trial results have prompted the field to reconsider the timing of intervention as well as the etiopathogenesis in AD, considering treatments during the asymptomatic or preclinical stages of disease and alternative pathobiology to the amyloid-centric thesis. The recent push in defining the preclinical AD stages has prominently featured both neuroimaging and cerebrospinal fluid (CSF) biomarkers. There is significant historical experience with both of these methods in symptomatic AD. Due to the associated cost and risk of these approaches, respectively, their use in asymptomatic subjects has been more difficult to justify and implement, limiting their utility in preclinical AD trial design. Our group has recently discovered and validated a series of human blood-based biomarker panels that accurately predict which cognitively normal septuagenarians will develop MCI or AD within the next 5 years. Not limited by either cost or risk, and showing comparable or greater accuracy than provided by neuroimaging or CSF biomarkers, we (and others) propose that bloodbased biomarkers are ready to be incorporated into preclinical AD disease-modifying clinical trials for selecting appropriate participants and tracking treatment effects.
The Development of ADS-5102 (Amantadine ER Capsules) for the Treatment of Levodopa-induced Dyskinesia Natalie McClure, Adamas Pharmaceuticals, Inc.
ADS-5102 is a long acting, extended-release capsule formulation of amantadine HCl administered once daily at bedtime. This study investigated the safety, efficacy, and tolerability of ADS-5102 in Parkinson's disease (PD) patients with levodopa-induced dyskinesia (LID). This was a randomized, double-blind, placebo-controlled, parallel-group study of 83 PD patients with troublesome LID assigned to placebo or one of three dose levels of ADS-5102 (260, 340, 420 mg) administered once nightly for 8 weeks. The primary efficacy analysis compared the change from baseline to week 8 in the Unified Dyskinesia Rating Scale (UDysRS) total score for 340 mg ADS-5102 versus placebo. Key secondary analyses (including other UDysRS dose level comparisons) utilized a hierarchical procedure to control the overall level of significance. Other secondary outcome measures included the Fatigue Severity Scale (FSS), Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), PD patient diary, Clinicians Global Impression of Change (CGI-C), and the Parkinson's Disease Questionnaire (PDQ-39). ADS-5102 significantly reduced LID, as measured by change in the UDysRS total score over 8 weeks versus placebo, at both the 340 mg (p=0.005) and 420 mg (p=0.013) dose levels. In addition, 340 mg ADS-5102 significantly increased ON time without troublesome dyskinesia by 3 h (p=0.008) and reduced OFF time (0.9 h, p=0.199) as assessed by PD patient diaries. The most common adverse events were constipation, hallucinations, dizziness, and dry mouth. ADS-5102 is now being tested in three phase 3 studies.
Pipeline Session F T-0 1 2 f o r t h e Tr e a t m e n t o f A c u t e H e p a t i c Encephalopathy
Gregory Frykman, Westhaven Pharmaceuticals, LLC FT-012 is a synthetic tectosilicate that selectively adsorbs cations such as ammonia, strontium, cadmium, zinc, lead, and cesium and is undergoing development for the treatment of hepatic encephalopathy (HE). In vitro studies have demonstrated the ammonia binding activity of FT-012 of 83 to 95 % of ammonia at the 120 ppm level and similar sequestration at an approximate doubling of the ammonia concentration. FT-012 adsorbs lead and cesium with an affinity approximately similar to and higher than ammonia, respectively. FT-012 has demonstrated in vivo activity in a rodent HE model with an approximate 40 % reduction in portal venous ammonia levels when administered after the animals had been rendered hyperammonemic. In a porcine model of HE, FT-012 demonstrated a dose-dependent decrease in systemic venous ammonia, and in an ovine HE model, FT-012 reduced systemic venous ammonia levels by 40 %. In bovines exposed to high amounts of ammonia generating food supplements, FT-012 reduced circulating venous ammonia and improved symptoms of HE. Pharmacokinetic studies in rats, dogs, and primates showed that FT-012 is not absorbed from the gastrointestinal tract and it is fecally eliminated. Acute and chronic toxicology studies (including 2-year carcinogenicity in rats) revealed no overt symptoms of toxicity even at very high FT-012 doses. FT-012 is not mutagenic, teratogenic, clastogenic, or genotoxic in any in vitro or in vivo system studied to date. FT Inflammation is one of the most important causes of cerebral palsy (CP) especially in premature infants who are often exposed to intrauterine infections as a cause of premature labor. White matter injury of this type is currently the most important cause of CP in the US accounting for about 80 % of all cases. This type of injury has been modeled in rabbits by injecting lipopolysaccharide (LPS) derived from the walls of gram negative bacteria. When LPS is injected directly in to the uterus of a pregnant rabbit on gestational day 28 before term delivery on day 31, the kits are born with stiffness of the legs and inability to hop and move about resembling CP in human babies. After the CP phenotype is clearly established in the postnatal period, half the animals were injected intravenously with dendrimers with N-acetyl-L-cysteine (D-NAC) attached, and another group of animals was injected with dendrimers without NAC (D) attached. Behavioral testing showed that the LPS-injected animals without D alone remained unable to walk, hop, or feed over two postnatal weeks after which they died. On the other hand, D-NAC-treated animals recovered without CP and histology showed that there was much less inflammation in the white matter than in the untreated kits. The mechanism of toxicity of LPS appears to be selective damage to the pre-oligodendrocytes that are vulnerable to both infection-inflammation and hypoxia-ischemia in the human preterm brain. Examination of levels of inflammatory cytokines in the brains of LPS-treated rabbit kits are elevated while inflammatory cytokines in LPS-treated kits treated with D-NAC are reduced to normal levels. D-NAC therapy appears to have a favorable profile of toxicity in humans treated for macular degeneration, and this therapy has potential as a therapy for human premature babies who develop CP, and it would have the advantage that it would be possible to firmly establish the diagnosis of CP before starting treatment. Allogeneic mesenchymal stem (stromal) cells (MSCs) have long been considered an emerging therapeutic modality for ischemic stroke. But while displaying convincing safety and efficacy in rodent models, results from the limited human trials conducted to date have been less encouraging. Here, we compared potential determinates of human utility in rat models of ischemic stroke. NCS-01 is a human adult bone marrow-derived MSC product. Using the in vitro oxygen glucose deprivation model containing rat neurons and astrocytes, protection efficacy averaged 80 % and rescue efficacy 50 % (p<.05). NCS-01 increased the concentration of bFGF and IL-6, cytokines of potential neuroprotective/neurorestorative benefit, into the co-culture media at rates nearly tenfold above controls (p<.05). In the rat, in vivo, middle cerebral artery occlusion model, rescue averaged 38 % neurologically and 65 % pathologically (p<.05). NCS-01 infusion via the ipsilateral carotid artery proved more effective than via the ipsilateral jugular vein; delivery 3-24 h after the ischemic insult appeared maximally beneficial; doses ranging from 7.5×105 Neuroinflammation is critical to the progression of Parkinson's disease (PD). Current symptomatic therapies do nothing to mitigate this problem, and the failure of antiinflammatory approaches in clinical trials underscores the need for more effective therapies to combat this condition. Loss of dopamine-producing neurons in PD is accompanied by inflammatory activation of surrounding microglia and astrocytes, leading to the overproduction of neurotoxic inflammatory mediators that further damage dopaminergic neurons, inducing a cycle of inflammatory damage that ultimately contributes to the progression of the disease and the worsening of motor symptoms. Recent evidence indicates that the expression of neuroinflammatory genes in glial cells is regulated by the nuclear receptor, NR4A2 (Nurr1), which is highly expressed in dopaminergic brain regions. Interest in Nurr1 as a neuroprotective target in PD is high but there are no approved drugs that activate this receptor to stimulate its anti-inflammatory activity. Studies in our laboratory examined a unique serious of small molecule entities with high selective activity toward Nurr1 that demonstrate anti-inflammatory and neuroprotective efficacy both in vitro and in vivo. Selected molecules in this series have high oral bioavailability, favorable pharmacokinetic distribution to the brain, and show extremely low toxicity in initial in vivo safety studies. Using the MPTP/probenecid model of parkinsonism, we demonstrated that several molecules in this series prevented loss of dopamine neurons in mice, even when delivered orally 1 week after administration of MPTP/probenecid. Related in vitro studies using RNAi to decrease expression of Nurr1 in glial cell lines indicated that the presence of Nurr1 is required for the antiinflammatory effects of C-DIM12. Collectively, these data suggest that C-DIM12 and related molecules could be strong candidates for further pre-clinical and clinical development.
Pipeline Session
Nanoparticles for Direct Nose-to-Brain Delivery of Gene Therapy J. Sanchez-Ramos, S. Song and V. Sava, University of South Florida Background: A major obstacle to fulfilling the therapeutic promise of gene silencing technology for brain disease is the requirement for an invasive delivery system: stereotaxic injection of viral vectors or infusion directly into brain or intrathecal space. Aims: (1) To design and optimize nanoparticles loaded with either siRNA or dsDNA in a cell culture system expressing green fluorescent protein (GFP) and (2) to assess the capacity of nanocarriers instilled into nasal mucosa of mice to carry and distribute payloads of siRNA or dsDNA to brain. Methods: Manganese-containing nanoparticles (mNPs) carrying anti-GFP siRNA or dsDNA encoding red fluorescent protein (RFP) were fabricated and tested in a cell culture system of eGFP-expressing cell line of mouse fibroblasts (NIH3T3). The optimal mNP loaded with anti-GFP siRNA or dsDNA encoding RFP was then administered intranasally in Tg GFP mice and C57BL6J mice.
Results: mNPs loaded with anti-GFP siRNA were effective in decreasing GFP fluorescence by 73 % compared to control cultures, similar to Lipofectamine anti-GFP siRNA treatment. Following intranasal delivery, mNPs were visualized by 7T MRI in olfactory bulb and four regions of brain analyzed (olfactory bulb, striatum, hippocampus, and cortex). In Tg GFP mice, mNPs were effective in significantly reducing GFP mRNA expression in all four regions. Intranasal instillation of mNPS loaded with dsDNA encoding RFP resulted in expression of RFP in olfactory bulb, ventral striatum, hypothalamus, and other regions. Conclusions: Intranasal delivery of mNPs carrying a payload of anti-GFP siRNA (or dsDNA encoding RFP) was effective in decreasing GFP mRNA expression or in expressing RFP protein, respectively, in multiple brain regions. Mechanisms responsible for transport and dissemination of the mNPs are complex and will require further research. This approach for delivery of gene therapies to humans, if successful, will have a significant impact on disease-modifying therapeutics of neurodegenerative diseases.
Pipeline Session Novel Tablet Design for Easy and Accurate Dose Adjustments for Neurotherapeutics
John Siebert, PhD, Chase Pharmaceuticals Corporation; Robert Goldfarb, JD, Elliot Hahn, PhD, Accu-Break Pharmaceuticals, Inc.
Treatment with neurotherapeutics, including antidementia, antidepressants, antiepileptics, movement disorders, and antipsychotics, often requires careful start low, go slow titrations, ongoing dose adjustments in response to side effects, and careful down titration when discontinued. To manage regimens, physicians often need to prescribe alternating daily dosages, multiples of one dose, and/or split tablets. This can be challenging and potentially expensive with capsules and unscored tablets. Tablets bearing score marks generally have cosmetic scores and do not break evenly, introducing further risk and uncertainty into an already complex clinical situation. Accu-Break Pharmaceuticals has developed a novel tablet design that facilitates dose adjustments. The Accu-Break Tablet is a new patient-friendly, functionally scored tablet that can easily be broken by hand into exact smaller doses. The AccuBreak Tablet is manufactured using an innovative bi-layer structure that contains a deeply scored drug layer predivided into precise fractions. Under the drug layer is a placebo layer, which provides a convenient break zone within the tablet when a partial dose is needed. This unique design meets FDA's newly released Guidance for Industry for scored dosage forms. Accu-Break tablets are especially useful for narrow therapeutic index, highly potent, and pediatric drugs. They are also well suited for companion animal medications where weight-based dosing in a diverse patient population is standard. Market research conducted by Accu-Break and by Compan Pharmaceuticals (an animal healthcare company) validates that physicians, payers, and veterinarians believe the technology provides added value. Financial Sponsor: Accu-Break Pharmaceuticals, Inc.
Pipeline Session
Stroke and neurodegenerative disease is the leading cause of disability among older adults worldwide, and recent increases in life expectancy results in growing numbers of patients suffering from these diseases and global burdens. Accordingly, there is an increasing need for improving the efficiency of rehabilitative intervention, and at the same time, reducing its cost. Recently, novel 'neuromodulation techniques' including transcranial magnetic/current stimulation and neurofeedback, have drawn attention and have been introduced as augmenting tools for neurorehabilitation since these techniques can modulate brain activity and neuronal network status to facilitate functional recovery after brain damage. Neurofeedback is the technique in which subjects try to modulate their own neural activity voluntarily with realtime feedback using functional neuroimaging. As a functional neuroimaging technique for convenient and useful neurofeedback system to augment neurorehabilitation, we focused on functional near-infrared spectroscopy (fNIRS) which can detect regional cortical hemodynamic changes associated with the neuronal activation without onerous constraint to the patients, and developed a fNIRSmediated neurofeedback system. After we confirmed the neuromodulation effect with healthy subjects, we conducted the study investigating the clinical efficacy of the fNIRS-mediated neurofeedback system for stroke patients. Our preliminary, small RCT revealed that the neurofeedback intervention targeting the ips-lesional premotor cortex combined with mental practice using motor imagery of paretic hand enhanced functional recovery of the hand paresis. Now, we are conducting the study to investigate the therapeutic effect of fNIRS-mediated neurofeedback system for patients with neurodegenerative disease including Parkinson's disease and spinocerebellar degeneration, and other motor symptoms including gait and balance impairment.
In addition, we are also developing the portable neurofeedback system in collaboration with developer companies of NIRS, to maximize its clinical usefulness. Our novel fNIRS-mediated neurofeedback system could be a safe, less onerous, and less expensive neurorehabilitation system to minimize disability-adjusted life-years (DALYs) in victims of neurological disease without increasing budget. Background: There is no effective treatment and many previous efforts using various neuroprotective agents did not prove successful in ALS. Recently, stem cell-based therapy is an emerging alternative therapeutic or disease-modifying strategy in ALS. Objectives: On the basis of the previous animal study and the pilot clinical study, we sought to evaluate the safety and feasibility of repeated intrathecal administrations of autologous bone marrow-derived MSCs in patients with ALS. Methods: This study was designed as a single-center, randomized, open label, parallel-group, phase 1/2 trial (HYUH IRB 2010-C-70, KFDA-2413, clinicaltrials.gov: ID NCT01363401). In phase 1 trial, eight patients were enrolled. After lead-in period for 3 months, autologous MSCs were isolated from bone marrow, expanded in vitro, and suspended in autologous CSF; seven patients received an intrathecal MSCs (1×106/kg) injection twice at an interval of 1 month via a standard lumbar puncture. After the first MSC injection, clinical and laboratory measurements were recorded to evaluate its safety. In phase 2 trial, 59 patients (treatment group: 32, control group: 27) were enrolled. All treatment group received procedures same as phase 1 trial. Primary outcome measures the decline rate of ALSFRS-R score from baseline to 4 months. Occurrences of AE and SAE, all clinical and laboratory findings were collected for safety analysis. Changing ratio of ALSFRS-R between lead-in period and 6 month after MSCs injection. The changes of Appel score, forced vital capacity (FVC) were secondary outcome. Results: No significant major adverse events were reported during phase 1 and 2 trials. MSCs injection was well tolerable except for occurrences of transient headache, myalgia, and back pain. These AEs were disappeared spontaneously or with simple analgesics within 1 or 2 weeks. In phase 2 trial, ALSFRS-R decline rate was significant lower in treatment group compared to control group during the first 4 and 6 months follow-up period (0.42±0.64/month vs. 1.17 ± 0.81/month, p = 0.0002, 0.58 ± 0.68/month vs. 2010 ) have resulted in small, conformable, disposable epidermal electrodes that may act as sensors as part of a portable TBI diagnostic device. We aim to evaluate the feasibility of using novel flexible epidermal electrodes to detect TBI-induced changes in SSEPs. Methods: In anesthetized mice, we exposed the brain to high-intensity focused-ultrasound pulses that mimicked blast overpressure, to produce controlled brain injury (McCabe JT, et al. 2014 ). Immediately before ultrasound-induced injury and up to 1 h after, we electrically stimulated the median nerve and recorded SSEPs from the somatosensory cortex. Invasive epidural electrodes, with a high signal-to-noise ratio, were used in one group of animals as a comparison; non-invasive flexible epidermal electrodes were tested in another group of animals. Results: In the cohort implanted with standard epidural electrodes, the SSEP peak amplitudes were reduced immediately after ultrasound exposure. Likewise, in cohort with epidermal electrode recordings, we obtained comparable SSEP dynamics, although with reduced signal amplitude. Epidermal electrode recordings are sensitive to different severity of brain injury produced by graded ultrasound exposure. Background: Penetrating microelectrode arrays (MEAs) sample neural data at high spatial and temporal resolution, providing input for neuroprosthetics and other potential therapeutic or assistive interventions. The utility of these implants is limited by the degradation of recorded signals over time, an effect that may have both biotic and abiotic causes. Biotic sources of signal loss include the brain s immune response, which is activated by breaching the blood-brain barrier with the implant. However, the extent of this reaction varies greatly and published reports differ on neuronal effects. A clear link between tissue and device performance remains to be drawn. Here, we assess the three-dimensional organization of the neuroinflammatory reaction to a penetrating probe by leaving the device and surrounding tissue intact. In a parallel set of experiments, we explore neuroinflammatory markers expressed after chronic implantation periods, and associated effects on laminar reconstruction and cortical atrophy. Methods: All animal procedures complied with the National Institutes of Health Guide for Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at each institution. Device capture IHC was implemented to obtain a threedimensional view of the immune response surrounding cortical implants. Single shank non-functional probes were inserted into the cortex of adult female Long Evans rats (n= 8) for up to 8 weeks. Brains were sliced, such that one slice contained the entire probe, and then labeled for neurons (NeuN), astrocytes (GFAP), activated microglia/ macrophages (CD68), and all cellular nuclei (DAPI). The neuroinflammatory response of different commercially available MEAs was investigated by implanting adult male B6 mice with cortical probes from either NeuroNexus (n=7) or Blackrock (n=3). Weekly recordings were performed from awake mobile mice until spikes could no longer be detected (mean=9 months). Probes were removed from the brain for explant measurements, and tissue slices were labeled for neurons (NeuN), astrocytes (GFAP), microglia (Iba1), and all cellular nuclei (DAPI). Cortical atrophy and laminar reconstruction were also quantified. Results: Device capture IHC allowed for detailed examination of the three-dimensional organization of cellular populations involved in the inflammatory response. We identified a small population of cells that were not labeled as neurons, astrocytes, or activated microglia/macrophages. These cells were always located adjacent to the probe and coincided with a decrease in NeuN, paired with an increase in CD68 labeling. Following long-term implantation (Mean=9 months), cortical atrophy was significantly different from the contralateral hemisphere. Brains implanted with Blackrock devices additionally displayed significant swelling. GFAP labeling was most prominent adjacent to the device track for both NeuroNexus and Blackrock implanted brains. However, some of the brains implanted with Blackrock devices also showed systemic GFAP labeling on the contralateral hemisphere. Shifting of cortical layers was identified on most brains regardless of the implant type, but brains implanted with Blackrock devices illustrated additional cortical reconstruction including ventricle enlargement, midline shifting, and white matter changes. Despite gross morphological changes, neuronal signals were still identified in these recordings. Background: Currently, there are no widely used diagnostic or therapeutic medical products for mild brain injury, partly due to the lack of objective biomarkers for measuring outcomes. Electrophysiological indices, such as quantitative EEG (qEEG), have the potential to serve as biomarkers for neural damage. Recent advances in EEG recording technology may soon allow for rapid, non-invasive signal detection on inexpensive and portable platforms. However, the signature changes in neural activity that accompany mild brain injury need to be established. In our study, we identify electrophysiological signatures of mild brain injury in a novel mouse model. Methods: Controllable high-intensity focused ultrasound (HIFU) pulses that mimicked blast overpressure waves were used to produce brain injury in mice [1] . HIFU-induced brain injury was evaluated by immunohistochemical markers for microglial activation (Iba-1) and astrocyte reactivity (GFAP), as well as by locomotor behavioral testing with a rotarod. Brain activity was recorded with a 16-channel epidural micro-electrocorticography (μECoG, Neuronexus) array implanted on the primary motor cortex. Periodic recordings (twice per week) from freely moving animals were performed for four consecutive weeks before and after either HIFU or sham exposure. The frequency content of all electrophysiological signals was quantified by multitaper fast fourier transform (FFT) following artifact rejection [2] . Results: Immunohistochemical labeling demonstrated elevated expression of Iba-1 and GFAP in the cortex, corpus callosum, and hippocampus 2, 24 h, and 1week after HIFU exposure, suggesting a diffuse neuroinflammatory response. This is in agreement with previous reports [1, 3, 4] . Animals subjected to HIFU exposure exhibited significantly poorer performance in the rotarod behavioral tests than those with a sham exposure up to 1 month postinjury, indicating a chronic functional impairment in locomotor ability. Our preliminary μECoG signals showed an acute increase in power in the alpha and beta frequency bands, and a long-term reduction in the delta band after brain injury. Additionally, there was a trend of reduction in signal coherence between electrodes after the injury. We are now validating our preliminary electrophysiological findings by increasing the number of animals in each cohort. The charts of 130 consecutive Dravet syndrome patients followed-up at the Ann & Robert H. Lurie Children's Hospital (Chicago, IL) since 2002 were reviewed. The review showed that 29 patients were treated with stiripentol (STP), 22 were also treated with clobazam (CLB), and 7 were not receiving CLB. Prior to receiving STP, 16 of 22 patients on CLB had their dose of CLB titrated upward, until no further efficacy was observed, or until dose-limiting adverse events (AEs) were observed, or until three times the therapeutic dose was reached, whichever came first; 14 of these 16 patients experienced severe sedation (lethargy) at the highest CLB dose reached prior to STP treatment, but continued to present with seizures. Results showed that when STP was added on to their AED treatment, 12 of the above 16 patients had a ≥50 % reduction in seizure frequency, and half had ≥90 % reduction in seizure frequency. Furthermore, four of six patients who did not titrate their dose of CLB to maximum tolerated dose had a ≥50 % reduction in seizure frequency when STP was added on to their treatment. Interestingly, five of seven patients who were not receiving CLB had a ≥50 % reduction in seizure frequency when STP was added on to their treatment. These results support that the contribution of CLB and NCLB to the efficacy of STP is minimal since 12 of 16 (75 %) patients titrated up to maximum effective or maximal tolerated dose of CLB still had an additional ≥50 % reduction in seizure frequency when treated with STP. added on to optimized treatment with VPA and CLB significantly reduced seizure frequency compared to placebo. In both trials, STP treatment was associated with increased plasma concentrations of CLB and its metabolite, norclobazam (NCLB). To assess the independent contribution of increased plasma concentrations of CLB and NCLB to the efficacy of STP, a covariate adjusted analysis was performed, using a logistic model where the dependent variable was treatment response, defined as reduction by ≥50 % of generalized tonic-clonic seizures (GTCS) or generalized clonic seizures (GCS) and the independent variables were treatment (STP or placebo), along with the change from baseline in CLB and NCLB plasma concentrations. A logistic model with STP as independent variable and (i) no adjustment for CLB or NCLB; (ii) a single covariate (change from baseline in CLB or NCLB plasma concentrations); and (iii) two covariates (change from baseline in CLB and NCLB plasma concentrations) were used. There was a significant decrease in the frequency of GTCS and GCS in the STP group versus placebo for each trial independently, STICLO France (p<0.0001) and STIC LO Italy (p=0.0098), and for both trials pooled (p<0.0001; OR=28.56). After adjusting for either CLB or NCLB, there was no statistically significant effect of increased CLB or NCLB plasma concentrations on treatment (STP or placebo) response. Based on the ODDS ratio analysis, the increases in CLB and NCLB plasma concentrations made a nonsignificant contribution [p=0.5038, and p=0.6628, The efficacy of tetrabenazine (TBZ) on chorea in Huntington disease (HD) was demonstrated in TetraHD, a 12-week, multicenter, prospective, randomized, double-blind, placebocontrolled study in two parallel unbalanced (2:1) groups (TBZ titrated to "best dose", N=54; placebo, N=30) of HD patients (Marshall and the Huntington Study Group, 2006). Study drug dosage was adjusted upward by weekly 12.5-mg increments during the first 7 weeks of the study, starting at 12.5 mg/day, until desired efficacy was observed or doselimiting AEs supervened, or the maximum dose of 100 mg/ day had been reached. In case of dose-limiting AEs, investigators were instructed to reduce the dose of TBZ to a dose at which the AE resolved or was tolerable. AEs associated with TBZ, were therefore expected to be primarily associated with upward dosage titration, and this was confirmed in TetraHD. A total 49 of 54 (91 %) TBZ patients reported one or more AEs at any time during the study compared to 21 of 30 (70 %) placebo patients. Only 19 (31 %) TBZ patients reported AEs during maintenance. The most commonly reported AEs with TBZ were fatigue (22 %), insomnia (22 %), depression (15 %), fall (15 %), sedation (15 %) and with placebo, fatigue (13 %), fall (13 %), coughing (10 %), and diarrhea (10 %). Noteworthy differences between titration and maintenance period in the TBZ group include sedation (15 % versus 0 %), depression (13 % versus 2 %), irritability (7 % versus 1 %), restlessness aggravated (11 % versus 2 %), akathisia (9 % versus 0 %), bradykinesia (6 % versus 0 %), fatigue (20 % versus 2 %), nausea (13 % versus 0 %), and falls (13 % versus 6 %). A similar trend was observed in the open-label long-term extension study to TetraHD. While 74 of 75 patients reported one or more AEs during titration (weeks 0-12), 35 (weeks 13-24), 25 (weeks 25-36), 20 (weeks 37-48), 17 (weeks49-60), 13 (weeks 61-72), and 22 (weeks 73-84) patients reported one or more AEs during the maintenance phase of the study. Thus, it can be concluded that AEs with TBZ occur mainly during the upward dose titration.
